Ignite Creation Date:
2024-05-06 @ 8:22 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06353022
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-04-08
First Post:
2024-03-22
Brief Title:
Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab Bortezomib Lenalidomide and Dexamethasone D-VRd in Newly Diagnosed Multiple Myeloma
Sponsor:
Nantes University Hospital
Organization:
Nantes University Hospital
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-04-20
Start Date Type:
ESTIMATED
Primary Completion Date:
2026-04-20
Primary Completion Date Type:
ESTIMATED
Completion Date:
2030-06-20
Completion Date Type:
ESTIMATED
First Submit Date:
2024-03-22
First Submit QC Date:
April 3 2024
Study First Post Date:
2024-04-08
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-04-03
Last Update Post Date:
2024-04-08
Last Update Post Date Type:
ACTUAL